Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabEase: Subcutaneous vs Intravenous Rituximab with CHOP in DLBCL
NCT01649856Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2012
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Aug 2012; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01649856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649856.